IQ EQ FUND MANAGEMENT IRELAND Ltd Has $882,000 Position in Cencora, Inc. $COR

IQ EQ FUND MANAGEMENT IRELAND Ltd lessened its holdings in shares of Cencora, Inc. (NYSE:COR) by 48.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,822 shares of the company’s stock after selling 2,635 shares during the quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd’s holdings in Cencora were worth $882,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in COR. Mirae Asset Global Investments Co. Ltd. lifted its stake in Cencora by 13.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 48,270 shares of the company’s stock valued at $15,086,000 after acquiring an additional 5,543 shares in the last quarter. Acadian Asset Management LLC grew its stake in shares of Cencora by 947.5% in the 2nd quarter. Acadian Asset Management LLC now owns 257,082 shares of the company’s stock worth $77,069,000 after acquiring an additional 232,539 shares in the last quarter. Mediolanum International Funds Ltd raised its holdings in shares of Cencora by 133.0% in the third quarter. Mediolanum International Funds Ltd now owns 56,293 shares of the company’s stock valued at $17,342,000 after purchasing an additional 32,138 shares during the last quarter. Segment Wealth Management LLC bought a new position in shares of Cencora during the third quarter valued at about $4,830,000. Finally, Synergy Asset Management LLC purchased a new position in Cencora during the third quarter worth about $10,093,000. 97.52% of the stock is owned by institutional investors.

Key Stories Impacting Cencora

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: Q1 2026 earnings call highlighted strong U.S. growth that offset international headwinds; management commentary helped support the upbeat tone after results. Cencora Inc (COR) Q1 2026 Earnings Call Highlights
• Positive Sentiment: Cencora closed its deal with OneOncology; coverage of the terms characterizes the agreement as reflecting trust between parties, which supports the company’s oncology services strategy and potential revenue synergies. As Cencora Closes With OneOncology
• Neutral Sentiment: Evercore ISI set a new $420 price target (down from $440) but kept an “outperform” rating — the target implies meaningful upside from current levels despite the trim. Cencora Given New $420.00 Price Target at Evercore ISI
• Neutral Sentiment: Market write-ups and stock-flow coverage are highlighting the mix of EPS beats and revenue dynamics as reasons for the intraday move, keeping attention on upcoming guidance and international performance. Cencora stock trades up, here is why
• Negative Sentiment: Cencora missed Q4 CY2025 revenue estimates, which tempers enthusiasm from the EPS beat and raises questions about near-term revenue momentum. Cencora misses Q4 revenue estimates
• Negative Sentiment: Recent intraday coverage noted the stock underperformed peers on Wednesday, suggesting investors are watching competitive execution and margin trends across the sector. Cencora underperforms competitors

Insider Activity at Cencora

In related news, EVP Elizabeth S. Campbell sold 3,351 shares of the firm’s stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $342.10, for a total value of $1,146,377.10. Following the completion of the transaction, the executive vice president directly owned 23,891 shares of the company’s stock, valued at approximately $8,173,111.10. This trade represents a 12.30% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Silvana Battaglia sold 1,677 shares of Cencora stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $345.00, for a total transaction of $578,565.00. Following the completion of the transaction, the executive vice president owned 18,796 shares of the company’s stock, valued at $6,484,620. This represents a 8.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 20,316 shares of company stock worth $7,151,265. 0.38% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. TD Cowen increased their price objective on shares of Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, November 10th. Barclays initiated coverage on Cencora in a research report on Monday, December 8th. They set an “overweight” rating and a $400.00 price target for the company. Evercore cut their price objective on Cencora from $440.00 to $420.00 and set an “outperform” rating on the stock in a research report on Thursday. Wells Fargo & Company upped their price objective on Cencora from $354.00 to $405.00 and gave the company an “overweight” rating in a research note on Tuesday, November 11th. Finally, Mizuho lifted their target price on Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a research note on Thursday, November 6th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, Cencora currently has an average rating of “Moderate Buy” and a consensus price target of $394.75.

Cencora Stock Performance

NYSE:COR opened at $359.15 on Friday. The company has a market capitalization of $69.67 billion, a P/E ratio of 43.17, a P/E/G ratio of 1.63 and a beta of 0.68. The business has a fifty day simple moving average of $345.91 and a two-hundred day simple moving average of $325.92. The company has a debt-to-equity ratio of 3.62, a current ratio of 0.92 and a quick ratio of 0.55. Cencora, Inc. has a 1 year low of $237.71 and a 1 year high of $377.54.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share for the quarter, topping the consensus estimate of $4.04 by $0.04. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The company had revenue of $85.93 billion during the quarter, compared to the consensus estimate of $86.12 billion. During the same quarter in the prior year, the company earned $3.73 EPS. The firm’s quarterly revenue was up 5.5% compared to the same quarter last year. On average, analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 2nd. Stockholders of record on Friday, February 13th will be given a $0.60 dividend. The ex-dividend date of this dividend is Friday, February 13th. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. Cencora’s payout ratio is 30.19%.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.